A kind of ozagrel-paeonol compound and its application
By designing the new Ozagrel-Danpiphenol compound, the problem of insufficient stability and solubility of existing conjugates is solved, effective inhibition of platelet aggregation and hypoxia damage is achieved, and the bioavailability of the drug is significantly improved and clinical application potential.
Patent Information
- Application Number
- CN202211440169.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-11-17
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2042-11-17
AI Technical Summary
Existing Ozagrel and Dalciphenol conjugates have problems in stability and solubility, limiting their effectiveness in clinical applications, especially the fast clearance rate and short half-life in vivo leading to low drug use efficiency.
A new type of Ozagrel-Danciphenolic compounds were designed to synthesize compounds with strong pharmacological activity and stability in the body through the principle of splicing, combining the effects of anti-platelet aggregation and anti-neuron cell hypoxia damage, and improving biological properties through pharmaceutical carriers Utilization.
It significantly prolongs the half-life of the drug, improves oral bioavailability, and provides an effective treatment plan for cardiovascular and cerebrovascular diseases caused by thromboembolic, especially in cerebral infarction or thrombotic cardiac and cerebral ischemia, which shows good inhibition of platelet aggregation. and the effect of protecting brain cells.
Smart Images

Figure CN115872934B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of pharmaceutical chemistry, and in particular to an ozagrel-paeonol compound and application thereof. Background Art
[0002] Cardiovascular and cerebrovascular diseases are the leading cause of death in the world, among which cerebral infarction is the most typical. Cerebral infarction, also known as ischemic stroke, accounts for 69.6% to 70.8% of strokes in my country. Due to its high incidence, mortality and disability rates, ischemic stroke has become a global focus of public health issues.
[0003] Thrombosis is the main pathological feature of cerebral infarction and cardiovascular disease, and its subsequent clinical manifestations include imbalance in brain supply (i.e., lack of sugar and oxygen) and arterial occlusion. Therefore, the view that combining prevention and treatment to intervene in thrombosis is the way to improve cardiovascular disease has received widespread attention.
[0004] Ozagrel is a potent thromboxane synthase inhibitor that can effectively inhibit the production of TXA2 from PGH2, thereby inhibiting platelet aggregation. It also has the effect of dilating blood vessels and increasing cerebral blood flow. However, its half-life is short (t 1 / 2 =0.764h), and its poor water solubility leads to poor compliance in clinical use, thus limiting its clinical applicability. Paeonol improves endothelial function by regulating nitric oxide synthase activity, and can play an anti-platelet aggregation role, thereby preventing thrombosis, improving cerebral blood circulation, and having a significant protective effect on brain tissue in reperfusion injury. However, paeonol has a fast clearance rate in the body, and combining the advantages of the two to develop new drugs is a new entry point.
[0005] Chinese patents CN201310419227 and CN201310422876 disclose a preparation method and medical use of a paeonol-ozagrel conjugate POC with the activity of preventing and treating platelet aggregation. The compound has the problems of poor stability and poor solubility, which poses a huge challenge to the development of pharmaceutical agents and clinical drugs. Summary of the invention
[0006] In order to solve the above technical problems, the present invention adopts the splicing principle to splice ozagrel and paeonol, and designs and synthesizes a new type of ozagrel-paeonol compounds. This type of compound has strong pharmacological activity, can resist platelet aggregation activity and resist the damage of nerve cells caused by hypoxia and glucose, and is stable in the body and has good oral bioavailability.
[0007] The present invention is achieved through the following technical solutions:
[0008] An ozagrel-paeonol compound has the following general formula (I):
[0009]
[0010] Wherein, R represents a substituent:
[0011]
[0012] The structural formula of the ozagrel-paeonol compound (PNC1-5) of the present invention is as follows:
[0013]
[0014] Preferably, the substituent represented by R is
[0015] The present invention also provides the use of the above-mentioned ozagrel-paeonol compounds in the preparation of drugs for preventing or treating cardiovascular and cerebrovascular diseases caused by thromboembolism.
[0016] Preferably, the cardiovascular and cerebrovascular disease is cerebral infarction or thrombotic myocardial and cerebral ischemia.
[0017] The compounds described in the present invention can specifically bind to anti-platelet aggregation targets, inhibit platelet aggregation, have a protective effect on damaged brain cells, and significantly prolong the drug half-life (t1 / 2=2.082h), and have potential application value.
[0018] The present invention also provides a drug for preventing or treating cardiovascular and cerebrovascular diseases caused by thromboembolism, comprising the above-mentioned ozagrel-paeonol compound and a pharmaceutically acceptable carrier.
[0019] The pharmaceutically acceptable carriers described in the present invention refer to conventional drug carriers in the pharmaceutical field, and from the specific classification point of view, include (but are not limited to): excipients, such as one or more of starch or water; fillers, such as one or more of starch, lactose, dextrin, sucrose, microcrystalline cellulose or mannitol; binders, such as one or more of pregelatinized starch, dextrin, cellulose derivatives, alginate, gelatin, polyvinyl pyrrolidone or polyethylene glycol; disintegrants, such as one or more of sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, microcrystalline cellulose, sodium carboxymethyl cellulose or cross-linked polyvinylpyrrolidone; lubricants, such as one or more of magnesium stearate, micropowdered silica gel, talc, hydrogenated vegetable oil, polyethylene glycol, sodium lauryl sulfate or glycerol; wetting agents. , such as one or more of water or ethanol; osmotic pressure regulators, such as one or more of sodium chloride, glucose, sucrose, sorbitol or mannitol; antioxidants, such as one or more of sodium sulfite, sodium bisulfite, sodium pyrosulfite, sodium thiosulfate or thiourea; solvents, such as one or more of water, glycerol, dimethyl sulfoxide, ethanol, polyethylene glycol, propylene glycol or vegetable oil; buffers, such as one or more of acetic acid / sodium acetate, citric acid / sodium citrate, lactic acid or tartaric acid / sodium tartrate; absorption promoters, such as quaternary ammonium compounds; surfactants, such as hexadecanol; adsorption carriers, such as one or more of kaolin or bentonite; in addition, other adjuvants, such as one or more of sunscreens, flavoring agents or sweeteners, may also be added.
[0020] Preferably, the dosage form of the drug is tablets, capsules, granules, suspensions, emulsions, solutions, syrups or injections, etc. It can be prepared by conventional methods in the art. The compound of the present invention can be administered orally or by injection in clinical practice.
[0021] Compared with the prior art, the present invention has the following beneficial effects:
[0022] Pharmacological experiments have found that the ozagrel-paeonol compounds described in the present invention have a certain inhibitory effect on platelet aggregation induced by arachidonic acid and ADP, and have a significant protective effect on nerve cells damaged by glucose and hypoxia. The pharmacokinetic results show good oral bioavailability and in vivo stability, providing a good reference drug for the treatment of cardiovascular and cerebrovascular diseases caused by thromboembolism, especially the research and development of drugs for cerebral infarction or thrombotic myocardial and cerebral ischemia. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1The inhibition rate of ozagrel-paeonol compounds on platelet aggregation; (A: The effect of different concentrations of ozagrel-paeonol compounds on AA-induced platelet aggregation. B: The effect of different concentrations of ozagrel-paeonol compounds on ADP-induced platelet aggregation. Compared with positive drugs and POC *P<0.05);
[0024] Figure 2 The effect of Ozagrel-Paeonol compound PNC3 on the survival rate of PC12 cells;
[0025] Figure 3 This is the drug-time curve of the ozagrel-paeonol compound PNC3. DETAILED DESCRIPTION
[0026] The present invention is further described below by means of specific implementation methods. The following examples are specific implementation methods of the present invention, but the implementation methods of the present invention are not limited to the following examples.
[0027] Example 1: Synthesis of Ozagrel-Paeonol Compound PNC1 ((3-(4-((1H-imidazol-1-yl)methyl)phenyl)-N-(2-acetyl-5-methoxyphenyl)acrylamide)
[0028]
[0029] (1) Synthesis of Ozagrel Acyl Chloride:
[0030] Take 1.2 times the equivalent of ozagrel, 165.6 mg, and place it at the bottom of a 25 mL round-bottom flask. Add 1 drop of DMF (N, N-dimethylformamide), then add 0.5 ml of SOCl2, stir, and heat until it is completely dissolved. Reflux in an oil bath at 80°C for 5 hours, and monitor the reaction on a plate (add 1 drop of methanol to an EP tube, draw the reaction solution with a capillary and blow it into a plastic EP tube, and detect it on a thin layer plate. Ethyl acetate is used as a developing agent to monitor the formation of acyl chloride). After the reaction is completed, use a vacuum rotary evaporator to spin out the remaining SOCl2 to obtain ozagrel acyl chloride, and provide waterproof protection;
[0031] (2) Synthesis of PNC1:
[0032] 100 mg of paeonol derivative was dissolved in dichloromethane, and three times the equivalent of triethylamine was added as a catalyst. The mixture was slowly added dropwise to the acid chloride under ice bath conditions. After the addition was completed, the mixture was sealed with a nitrogen balloon and reacted at room temperature for 3 hours. After the reaction was completed, a yellow-brown oily liquid was obtained. Saturated sodium bicarbonate water and dichloromethane were added to extract repeatedly, and the sodium bicarbonate water was discarded. The remaining dichloromethane liquid was dehydrated with anhydrous sodium sulfate for 2 hours and then concentrated. Separation was performed on a preparative silica gel plate. The developing solvent was ethyl acetate: petroleum ether = 4:1. 26 mg of the product was isolated with a yield of 10.92%.
[0033] PNC1 compound hydrogen spectrum, carbon spectrum, high-resolution mass spectrometry analysis results:
[0034] 1 H NMR(MHz,CDCl3)δ12.49(s,1H),8.63(d,2.4Hz,1H),7.89(d,8.8Hz,1H),7.76(d,15.6Hz,1H),7.68(s,1H),7.63(s,1H) ,7.61(s,1H),7.24(s,1H),7.22(s,1H),7.17(s,1H),6.96(s,1H),6.69(s,1H),5.20(s,2H),3.96(s,3H),2.68(s,3H).
[0035] 13 C NMR (100MHz, CDCl3) δ201.36,164.95,164.90,144.00,141.22,137.45,134.95,133.73,130 .04,129.73,129.71,128.73,127.92,123.00,115.27,110.07,104.07,55.66,50.81,29.71.
[0036] ESI-HRMS: m / z calcd for C 22 H 21 N3O3[M+H]+376.1661found 376.1650.
[0037] Example 2: Synthesis of Ozagrel-Paeonol Compound PNC2 (3-(4-((1H-imidazol-1-yl)methyl)phenyl)-1-(4-(3-(2-acetyl-5-methoxyphenoxy)propyl)piperazine-1-yl)propenone)
[0038] (1) Synthesis of tert-butyl 4-(3-(4-((1H-imidazol-1-yl)methyl)phenyl)acryloyl)piperazine-1-carboxylate, an ozagrel derivative
[0039]
[0040] 3 g of ozagrel, 4.16 g of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, and 2.94 g of 1-hydroxybenzotriazole were put into a 50 mL round-bottom flask, and dichloromethane was added. The mixture was stirred at room temperature for two hours until dissolved. Then, 6.58 g of triethylamine and 4.04 g of 1-tert-butyloxycarbonylpiperazine were added, and the mixture was sealed and stirred for 1 hour. When the reaction was almost completely completed, saturated sodium bicarbonate water and dichloromethane were added for extraction, and anhydrous sodium sulfate was added to the extract to remove water, and then the extract was concentrated by a vacuum rotary evaporator, and then adsorption silica gel powder was added and dried to separate 6.2 g of tert-butyl 4-(3-(4-((1H-imidazole-1-yl)methyl)phenyl)acryloyl)piperazine-1-carboxylate;
[0041] (2) Synthesis of Ozagrel Intermediate PN (3-(4-((1H-imidazol-1-yl)methyl)phenyl)-1-(piperazin-1-yl)propenone)
[0042]
[0043] 2 g of tert-butyl 4-(3-(4-((1H-imidazole-1-yl)methyl)phenyl)acryloyl)piperazine-1-carboxylate was added to 20 mL of dichloromethane, and 5 mL of trifluoroacetic acid was added dropwise under ice bath conditions, and the mixture was sealed with a balloon and stirred at room temperature for 3 h; after the reaction was complete, saturated sodium bicarbonate water was added dropwise under ice bath conditions until no bubbles were generated, and then extracted with dichloromethane, and the extract was extracted with anhydrous sodium sulfate, and concentrated to obtain PN: 3-(4-((1H-imidazole-1-yl)methyl)phenyl)-1-(piperazine-1-yl)propenone;
[0044] (3) Synthesis of paeonol derivative 2-(3-chloro)propoxy-4-methoxyacetophenone
[0045]
[0046] 3 g of paeonol, 2.84 g of 1-bromo-3-chloropropane, and 2.49 g of anhydrous potassium carbonate were added to 10 mL of anhydrous acetonitrile, and the mixture was reacted for 4 h at 45 ° C under nitrogen protection. After the reaction was completed, the mixture was extracted with dichloromethane and saturated sodium bicarbonate water to obtain a wine red color. After dehydration and concentration, the mixture was separated by column chromatography to obtain 3.6 g of the product.
[0047] (4) Synthesis of Ozagrel-Paeonol Compound PNC2 (3-(4-((1H-imidazol-1-yl)methyl)phenyl)-1-(4-(3-(2-acetyl-5-methoxyphenoxy)propyl)piperazin-1-yl)propenone)
[0048]
[0049] At 45°C and nitrogen protection, add 5 mL of anhydrous N, N-dimethylformamide to 1 g of PN, 0.82 g of 2-(3-chloro)propoxy-4-methoxyacetophenone and 0.233 g of anhydrous potassium carbonate, and fully react for 4 hours; extract with dichloromethane and saturated sodium bicarbonate water, and separate by column chromatography. The separated liquid is evaporated under reduced pressure to remove the organic solvent to obtain a light yellow solid, and a small amount of ethyl acetate is added to homogenize to obtain a light yellow powder, i.e., 630 mg of PNC2.
[0050] PNC2 compound hydrogen spectrum, carbon spectrum, high-resolution mass spectrometry analysis results: 1 H NMR(400MHz,DMSO-d6)δ7.78(t,1.2Hz,1H),7.71(s,1H),7.69(s,1H),7.67(d,8.8Hz,1H),7.46(d,15 .6Hz,1H),7.28(s,1H),7.26(s,1H),7.25(d,15.2Hz,1H),7.20(t,1.2Hz,1H),6.92(t,1.2Hz,1H),6.6 3(d,2.4Hz,1H),6.60(dd,8.4,2.0Hz,1H),5.22(s,2H),4.16(t,6.0Hz,2H),3.83(s,3H),3.75-3.65( m,2H),3.63-3.53(m,2H),2.56-2.52(m,2H),2.51-2.50(m,3H),2.47-2.38(m,4H),2.04–1.94(m,2H).
[0051] 13 C NMR (100MHz, CDCl3) δ197.66,165.17,164.51,160.35,141.88,137.55,137.47,135.38,132.77,129.87,128.34,127 .70,121.22,119.30,117.75,105.02,99.13,66.55,55.58,55.04,53.68,52.82,50.50,45.75,42.09,32.02,26.47.
[0052] ESI-HRMS: m / z calcd for C 29 H 34 N4O4[M+H]+503.2658found 503.2639.
[0053] Example 3: Synthesis of Ozagrel and Paeonol Composite PNC3 (3-(4-((1H-imidazol-1-yl)methyl)phenyl)-1-(4-(4-(2-acetyl-5-methoxyphenoxy)butyl)piperazine-1-yl)propenone)
[0054] Steps (1) and (2) are the same as in Example 2;
[0055] (3) Synthesis of 2-(4-chloro)butoxy-4-methoxyacetophenone
[0056]
[0057] 3 g of paeonol, 3.1 g of 1-bromo-4-chlorobutane and 2.49 g of anhydrous potassium carbonate were added to 10 mL of anhydrous acetonitrile, and the mixture was reacted at 45°C under nitrogen protection for 4 h. After the reaction was completed, the mixture was extracted with dichloromethane and saturated sodium bicarbonate water, the extract was dehydrated and concentrated, and separated by column chromatography to obtain 4.5 g of the product;
[0058] (4) Synthesis of Ozagrel-Paeonol Compound PNC3 (3-(4-((1H-imidazol-1-yl)methyl)phenyl)-1-(4-(4-(2-acetyl-5-methoxyphenoxy)butyl)piperazin-1-yl)propenone)
[0059]
[0060] At 45°C and nitrogen protection, 1.24g PN, 1.182g 2-(4-chloro)butoxy-4-methoxyacetophenone and 0.313g anhydrous potassium carbonate were added to a round-bottom flask, followed by 5mL anhydrous N,N-dimethylformamide, and the reaction was continued for 4h. After the reaction was completed, the mixture was extracted with dichloromethane and saturated sodium bicarbonate water, the extract was dehydrated and concentrated, and separated by column chromatography to obtain 1.08g of light yellow PNC3 powder.
[0061] PNC3 compound hydrogen spectrum, carbon spectrum, high-resolution mass spectrometry analysis results:
[0062] 1H NMR(400MHz,DMSO-d6)δ7.76(t,1.2Hz,1H),7.71(s,1H),7.69(s,1H),7.67(d,8.4Hz,1H),7.46(d,15 .2Hz,1H),7.28(s,1H),7.26(s,1H),7.24(d,15.2Hz,1H),7.19(t,1.2Hz,1H),6.91(t,1.2Hz,1H),6.6 4(d,2.4Hz,1H),6.59(dd,8.8,2.4Hz,1H),5.21(s,2H),4.13(t,6.0Hz,2H),3.83(s,3H),3.73-3.63( m,2H),3.61-3.50(m,2H),2.50-2.48(m,3H),2.43-2.33(m,6H),1.90-1.78(m,2H),1.70-1.58(m,2H).
[0063] 13 C NMR (100MHz, CDCl3) δ197.70,165.14,164.48,160.43,141.77,137.57,137.48,135.39,132.72,130.03,128.31,127.66 ,121.25,119.27,117.81,104.96,99.01,68.26,57.90,55.55,53.50,52.86,50.45,45.82,42.17,32.07,27.08,23.47.
[0064] ESI-HRMS: m / z calcd for C 30 H 36 N4O4[M+H]+517.2815found 517.2799.
[0065] Example 4: Synthesis of Ozagrel-Paeonol Compound PNC4 (3-(4-((1H-imidazol-1-yl)methyl)phenyl)-1-(4-(5-(2-acetyl-5-methoxyphenoxy)pentyl)piperazin-1-yl)propenone)
[0066] Steps (1) and (2) are the same as in Example 2.
[0067] (3) Synthesis of 2-(5-chloro)pentyloxy-4-methoxyacetophenone
[0068]
[0069] 3 g of paeonol, 5.15 g of 1-bromo-5-chloropentane, and 2.49 g of anhydrous potassium carbonate were added to 10 mL of anhydrous acetonitrile, and the mixture was reacted at 45°C under nitrogen protection for 4 h. After the reaction was completed, the mixture was extracted with dichloromethane and saturated sodium bicarbonate water, the extract was dehydrated and concentrated, and separated by column chromatography to obtain 4.2 g of the product;
[0070] (4) Synthesis of Ozagrel-Paeonol Compound PNC4 (3-(4-((1H-imidazol-1-yl)methyl)phenyl)-1-(4-(5-(2-acetyl-5-methoxyphenoxy)pentyl)piperazin-1-yl)propenone)
[0071]
[0072] At 45°C and nitrogen protection, 0.2 g of PN, 0.181 g of 2-(5-chloro)pentyloxy-4-methoxyacetophenone, and 0.173 g of anhydrous potassium carbonate were placed in a round-bottom flask, followed by 5 mL of anhydrous N,N-dimethylformamide, and the reaction was continued for 4 hours. After the reaction was completed, the mixture was extracted with dichloromethane and saturated sodium bicarbonate water, the extract was dehydrated and concentrated, and separated by column chromatography to obtain 87 mg of a light yellow solid of PNC4.
[0073] PNC4 compound hydrogen spectrum, carbon spectrum, high-resolution mass spectrometry analysis results:
[0074] 1 H NMR(400MHz,DMSO-d6)δ6.77(t,1.2Hz,1H),6.72(s,1H),6.70(s,1H),6.67(d,8.4Hz,1H),6.47( d,15.2Hz,1H),6.29(s,1H),6.27(s,1H),6.25(d,15.2Hz,1H),6.20(t,1.2Hz,1H),5.92(t,1.2Hz ,1H),5.65(d,2.4Hz,1H),5.60(dd,8.8,2.4Hz,1H),4.22(s,2H),3.12(t,6.0Hz,2H),2.84(s,3H ),2.73-2.64(m,2H),2.60-2.50(m,2H),1.43-1.29(m,6H),0.88-0.76(m,2H),0.60-0.44(m,4H).
[0075] 13C NMR (100MHz, CDCl3) δ197.76,165.14,164.49,160.51,141.75,137.55,137.48,135.40,132.70,130.00,128.31,127.66,121.2 2,119.28,117.84,104.97,98.92,68.31,58.22,55.54,53.59,52.83,50.71,50.46,45.84,42.53,32.10,29.05,26.50,24.17.
[0076] ESI-HRMS: m / z calcd for C 31 H 38 N4O4[M+H]+531.2971found 531.2970.
[0077] Example 5: Synthesis of Ozagrel-Paeonol Compound PNC5 (3-(4-((1H-imidazol-1-yl)methyl)phenyl)-N-(3-(2-acetyl-5-methoxyphenoxy)propyl)acrylamide)
[0078] (1) Synthesis of 2-(3-tert-butylcarboxylatepropoxy)-4-methoxyacetophenone
[0079]
[0080] At 40°C and nitrogen protection, 206.25 mg of paeonol, 200 mg of tert-butyl (3-chloropropyl) carbamate, and 85.6 mg of anhydrous potassium carbonate were placed in a 25 ml volumetric flask, and 2 ml of anhydrous N, N-dimethylformamide was added to react for 4 hours. After the reaction was completed, dichloromethane and saturated sodium bicarbonate water were used for extraction to obtain a light yellow extract, which was concentrated under reduced pressure to obtain 240 mg of white 2-(3-tert-butyl formate propoxy)-4-methoxyacetophenone;
[0081] (2) Synthesis of 2-(3-amino)-propoxy-4-methoxyacetophenone
[0082]
[0083] 240 mg of 2-(3-tert-butyl formate propoxy)-4-methoxyacetophenone was placed in a round-bottom flask, 2.4 mL of dichloromethane and 0.6 mL of trifluoroacetic acid were added, the flask was sealed with a balloon and stirred at room temperature for 3 h; after the reaction was complete, saturated sodium bicarbonate water was added dropwise under ice bath conditions until no bubbles were generated, then extracted with dichloromethane, and the extract was extracted with anhydrous sodium sulfate and concentrated to obtain 125 mg of yellow 2-(3-amino)-propoxy-4-methoxyacetophenone oil;
[0084] (3) Synthesis of Ozagrel-Paeonol Compound PNC5 (3-(4-((1H-imidazol-1-yl)methyl)phenyl)-N-(3-(2-acetyl-5-methoxyphenoxy)propyl)acrylamide)
[0085]
[0086] At room temperature, 140.6 mg of ozagrel, 118 mg of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and 83.2 mg of 1-hydroxybenzotriazole were placed in a round-bottom flask, 2 mL of dichloromethane was added and stirred for 2 h, then 125 mg of 2-(3-amino)-propoxy-4-methoxyacetophenone and 0.257 ml of triethylamine were added, and the mixture was reacted for 1 h and separated by column chromatography to obtain 116 mg of white powder PNC5 3-(4-((1H-imidazole-1-yl)methyl)phenyl)-N-(3-(2-acetyl-5-methoxyphenoxy)propyl)acrylamide.
[0087] PNC5 compound hydrogen spectrum, carbon spectrum, high-resolution mass spectrometry analysis results:
[0088] 1 H NMR(400MHz,DMSO-d6)δ8.27(t,5.6Hz,1H),7.76(t,1.2Hz,1H),7.68(d,8.4Hz,1H),7.55 (s,1H),7.53(s,1H),7.40(d,16.0Hz,1H),7.27(s,1H),7.25(s,1H),7.19(t,1.2Hz,1H), 6.92(t,1.2Hz,1H),6.63(d,2.4Hz,2H),6.61(d,2.4Hz,2H),6.59(d,2.4Hz,1H),5.21(s, 2H),4.14(t,6.0Hz,2H),3.82(s,3H),3.41-3.38(m,2H),2.53(s,3H),2.00(q,6.4Hz,2H).
[0089] 13 C NMR (100MHz, CDCl3) δ197.32,166.33,164.71,160.16,138.80,137.47,136.99,135.77,133.90,129.88,128. 29,127.55,122.77,119.79,119.35,104.71,99.16,68.58,55.61,50.70,50.52,38.54,30.12,29.70,28.63.
[0090] ESI-HRMS: m / z calcd for C 25 H 27 N3O4[M+H]+434.2080found 434.2064.
[0091] Example 6: Study on the Antiplatelet Aggregation Activity of Ozagrel-Paeonol Compounds
[0092] Preparation of platelet-rich plasma (PRP) and platelet-poor plasma (PPP): Rabbits were fasted but not watered for 12-18 hours, and intraperitoneally anesthetized with 20% urethane, and blood was collected from the common carotid artery. The blood was centrifuged at 4°C, 1000r / min, and 15min in a siliconized centrifuge tube containing 3.8% sodium citrate solution (1:9). The upper beige suspension was aspirated to obtain platelet-rich plasma (PRP). The remaining plasma was centrifuged at 4°C, 3000r / min, and the supernatant was aspirated to obtain platelet-poor plasma (PPP).
[0093] The platelet count was adjusted to 1 × 10 8 PNC1, PNC2, PNC3, PNC4, PNC5, paeonol-ozagrel conjugate POC and ozagrel (positive drug) were dissolved in dimethyl sulfoxide, diluted with saline to different concentrations of 50μM, 100μM, 200μM, 400μM, 800μM, 1000μM, and then 10μL of different concentrations of the test compound and the positive control drug were added to the turbidity tube containing 260μL platelet-rich plasma, incubated at 37°C for 5min, and then 30μL of the inducer was added in sequence, the final concentration of the inducer adenosine diphosphate was 10μM, and the final concentration of the inducer arachidonic acid was 1mM. The maximum aggregation rate of the control tube and the test tube within 5min was measured by a platelet aggregation instrument, and the inhibition rate of the drug on platelet aggregation was calculated. Platelet aggregation inhibition rate (AIR) = (platelet aggregation rate of control group - platelet aggregation rate of experimental group) / platelet aggregation rate of control group × 100%. The results are shown in Table 1.
[0094] Table 1 IC50 values of ozagrel-paeonol compounds for inhibiting platelet aggregation in vitro
[0095]
[0096] Note: *Compared with Ozagrel group*P<0.05, # Compared with POC* / # P<0.05, ** / ## P<0.01
[0097] The results in Table 1 show that ozagrel-paeonol compounds have a certain inhibitory effect on platelet aggregation induced by adenosine diphosphate (ADP) and arachidonic acid (AA), among which the IC50 values of PNC3 and PNC1 are lower than those of ozagrel and POC, indicating that these two compounds are better than positive drugs and POC in inhibiting platelet aggregation induced by adenosine diphosphate (ADP) and arachidonic acid (AA) (*P<0.05 or # P<0.05); it also shows that PNC3 and PNC1 have better targeting to ADP and AA than other compounds. Figure 1 The results showed that PNC1 and PNC3 showed a certain dose-dependency in the range of 50-1000μM on ADP- and AA-induced platelet aggregation, and their antiplatelet activity was always better than that of POC. Compared with the two different induction methods, PNC1 and PNC3 were better than positive drugs in inhibiting ADP-induced platelet aggregation, and the anti-aggregation effect of PNC3 was also better than that of PNC1 (**P<0.05).
[0098] Example 7: Anti-hypoxia and glucose deficiency activity test of compound PNC3
[0099] (1) Detection of the toxicity of the drug molecule PNC3 of the present invention to PC12 cell line
[0100] PC12 cells in the logarithmic growth phase were selected and digested with 0.25% trypsin to prepare a single cell suspension. The density was adjusted to 1×10 5 The cell density was inoculated in a 96-well culture plate, and a blank group, a control group and a drug group were set up. Different concentrations of PNC3 were added to the drug group. PNC3 was diluted with culture medium to different concentrations of 5, 10, 20, 40, 80, 120, 240 μg / mL using the stock solution. 100 μL of incomplete culture medium was added to the blank wells, and 100 μL of cell suspension of the same concentration was added to the control wells and drug wells. Cultured in a 37°C incubator for 24 hours. The next day, 2 μL of the corresponding culture medium was added to the control wells and blank wells, and different concentrations of PNC3 solution were added to the drug group. After continued culture in the incubator for 24 hours, the original solution was aspirated, and 100 μL of 10% CCK-8 solution was added to each well, mixed, and cultured in the incubator for 2 hours. The absorbance value at 450 nm was measured using an enzyme marker. Finally, the survival rate of PC12 cells was determined based on the absorbance value. Cell viability = [(absorbance of experimental well - absorbance of blank well) / (absorbance of control well - absorbance of blank well)] x 100%.
[0101] The test results showed that: Figure 2As shown, the PNC3 compound has little effect on cell viability in the concentration range of 0-80 μg / mL (cell viability>90%) and has a certain degree of safety. When the concentration reaches 40 μg / mL, the cell activity gradually decreases but does not affect the cell viability.
[0102] (2) Detection of the effect of PNC3 on the survival rate of PC12 cells in the hypoxia-glucose injury model
[0103] The experiment was divided into three groups, namely blank group, control group and drug group (10μg / mL, 20μg / mL, 40μg / mL). The blank group was PC12 cells cultured normally for 26 hours; the control group was PC12 cells that were subjected to the glucose-hypoxia model for 2 hours, and then changed to normal culture medium and conditions for continued culture for 24 hours; the drug group was a group of PNC3 administered with different concentrations in the glucose-hypoxia model, and after 2 hours of glucose-hypoxia, changed to normal culture medium and conditions for continued culture for 24 hours, and different concentrations of the complex PNC3 were added throughout the glucose-hypoxia model process and normal culture.
[0104] PC12 cells in the logarithmic growth phase were selected to construct the oxygen-glucose deprivation injury (OGD / R) model. The cell density was 1×10 5 The cells were inoculated in a 96-well culture plate and cultured in RPMI1640 medium containing 1% FBS and the corresponding concentration of drugs. After 24 hours of routine culture, the OGD / R model was prepared. The next day, the RPMI1640 medium without glucose and serum was replaced, and the cells were cultured in a 5% CO2, 95% N2 three-gas incubator for 2 hours to complete the hypoxia process; cultured for 2 hours to complete the hypoxia process; then the cell culture medium was replaced with complete RPMI1640 medium (containing 10% heat-inactivated horse serum and 5% FBS), and the cells were placed in a 5% CO2 incubator for 24 hours to complete the reoxygenation process. 4 hours before the end of incubation, 100 μL of 10% CCK-8 solution was added to each well, and the cell survival rate was detected at a wavelength of 450 nm. As shown in Table 2, compared with the control group, PNC3 can significantly improve the survival rate of PC12 cells after hypoxia and glucose deprivation, and it is dose-dependent in the range of 10-40 μg / mL.
[0105] Table 2 Effect of PNC3 on the survival rate of PC12 cells in the oxygen-glucose deprivation injury model (n=6)
[0106]
[0107] Note: # Compared with the blank group ### P<0.001, *Compared with the control group *P<0.05, ***P<0.001
[0108] Example 9: Pharmacokinetic study of compound PNC3 in SD rats
[0109] In view of the poor solubility and low bioavailability of ozagrel and the fast clearance rate of paeonol in vivo, PNC3 with good brain protection is preferably introduced with a piperazine ring and a carbon chain in order to increase the water solubility of the structure and improve the metabolic changes in vivo, and provide data support for later dosage form development and drug research. Therefore, the LC-MS / MS analysis method is used to evaluate the difference in pharmacokinetics between tail vein and oral administration. The specific steps are as follows:
[0110] Twelve 220g-260g male SD rats were randomly divided into two groups, six in each group. They were fasted but not watered one day before administration. At the same time, 6.4mg / kg PNC3 (the dosage was based on the clinical dosage and converted by body surface area) was injected into the tail vein and gavage into the two groups of SD rats. Blood was collected from the canthus at 3min, 10min, 30min, 1h, 2h, 3h, 4h, 6h, 8h, and 12h after administration. Heparin sodium anticoagulation was used, and the supernatant was centrifuged at 3500r / min for 10min, and then analyzed by LC-MS / MS.
[0111] The concentration of PNC3 in plasma after intravenous injection and oral administration was analyzed and compared, and the drug-time curve was fitted using origin software. The results showed that (see Figure 3 ): The drug concentration of compound PNC3 gradually became undetectable 6 hours after administration by tail vein injection, but reached the highest drug concentration 1 hour after oral administration and was gradually metabolized completely in 8 hours. The half-life of the drug by tail vein and oral administration was 124.945min and 290.961min, respectively. The relative oral bioavailability of oral administration was 33.1%, and the average residence time was significantly prolonged by 2.11 times. The above data suggest that PNC3 is a drug with development potential for the treatment of cerebral infarction or myocardial infarction caused by platelet aggregation, and has the potential to be developed into an oral preparation.
[0112] The pharmacokinetic parameters of the blood drug concentrations of PNC3 administered by tail vein and oral gavage were calculated, and the data fitting was performed using DAS 2.0 pharmacokinetic software. The specific results are shown in Table 3.
[0113] Table 3 Whole blood pharmacokinetic parameters after intragastric injection and tail vein PNC3 (n=6)
[0114]
Claims
1. An ozagrel-paeonol compound, It is characterized in that It has the following general formula (I): ; (I) Wherein, R represents a substituent:
2. The ozagrel-paeonol compound according to claim 1, It is characterized in that The substituent represented by R is .
3. Use of the ozagrel-paeonol compound according to claim 1 or 2 in the preparation of a medicament for preventing or treating a disease caused by platelet aggregation.
4. The use according to claim 3, It is characterized in that The disease is cerebral infarction or myocardial infarction.
5. Use of the ozagrel-paeonol compound according to claim 1 or 2 in the preparation of a drug for resisting neuronal cell damage caused by hypoxia and glucose.
6. A drug for preventing or treating a disease caused by platelet aggregation, comprising the ozagrel-paeonol compound according to claim 1 and a pharmaceutically acceptable carrier.
7. The drug for preventing or treating a disease caused by platelet aggregation according to claim 6, It is characterized in that The dosage form of the drug is tablet, capsule, granule, suspension, emulsion, syrup or injection.
